Global Oncology Drugs Market – Top 10 Pharma 2013 & 2020

Global Oncology Drugs Market – Top 10 Pharma 2013 & 2020

The global oncology drugs market, 2013 and 2020 (alkaloids, alkylating agents, anti-metabolites, anti-neoplastic MAbs, cancer vaccines, cytotoxic antibiotics, hormone therapies, platinum compounds and other anti-cancer drugs) has been analyzed for the top 10 pharmaceutical companies: Roche, Bristol-Myers Squibb, Celgene, Novartis, Pfizer, Johnson & Johnson, Astellas Pharma, AstraZeneca, Eli Lilly, and Merck & Co.

Roche dominates the oncology drugs market representing almost one-third of the entire market during 2013- 2020, followed by Novartis and Celgene. The compound average growth rate (CAGR 2017-2021) has been predicted to be higher at 19%, 15%, 33%, and 28% for Bristol-Myers Squibb, Pfizer, Astellas Pharma, and Merck & Co., respectively. However, in 2020, Bristol-Myers Squibb is most likely to occupy the second position.

Despite losing about 12-14% market share in 2020, Roche continues to dominate the oncology drugs market representing almost one-third of the entire market during 2017-2021. Novartis and Celgene are likely to lose about 5-7% and 2-3% oncology drugs market share till 2020 due to competitor products and cannibalism from biosimilars. The compound average growth rate (CAGR 2017-2021) has been predicted to be higher at 19%, 15%, 33%, and 28% for Bristol-Myers Squibb, Pfizer, Astellas Pharma, and Merck & Co., respectively. The market shares for Bristol-Myers Squibb, Pfizer, Astellas Pharma, and Merck & Co., are likely increase till 2020 by 3%, 1%, 3%, and 2%, respectively.

2017-11-03T10:36:57+00:00 Categories: Analyst Insights|